{
    "2019-02-28": [
        [
            {
                "time": "2018-02-28",
                "original_text": "格隆汇港股聚焦(2.28)︱中国铁塔下周一公布业绩 澳博控股2018年度纯利升45.2%至28.5亿港元",
                "features": {
                    "keywords": [
                        "中国铁塔",
                        "业绩公布",
                        "澳博控股",
                        "纯利增长"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "通信",
                        "博彩"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-03-01",
                "original_text": "A股头条之上市公司公告精选（3.1）",
                "features": {
                    "keywords": [
                        "上市公司公告"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "上海医药：终止两项药物的临床试验",
                "features": {
                    "keywords": [
                        "上海医药",
                        "临床试验终止"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "上海医药(02607.HK)：终止重组人肿瘤坏死因子受体突变体-Fc融合蛋白注射液及注射用多替泊芬临床试验 并购重组异常",
                "features": {
                    "keywords": [
                        "上海医药",
                        "临床试验终止",
                        "并购重组异常"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019",
                "original_text": "2019，医药冷链如何乘坐政策之风发展？",
                "features": {
                    "keywords": [
                        "医药冷链",
                        "政策影响"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}